Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study

Table 3 Factors affecting the extent of changes in plaque score using a linear mixed regression model

	Applied with the disease activity, DAS-28-ESR, at baseline	Applied with the disease activity, DAS-28-ESR, at Week 156
	Plaque score Regression coefficient (95% confidence interval) P value
Female sex	-1.12 (-2.106 – -0.134) 0.0264*	-1.221 (-2.197 – -0.246) 0.0147*
Age (≥ 65 years)	-0.33 (-1.033–0.373) 0.3536	-0.373 (-1.074–0.329) 0.2944
BMI (≥ 25 kg/m²)	-0.105 (-1.408–0.838) 0.8262	-0.059 (-0.166–0.048) 0.2767
Current or ex-smoker	-0.359 (-1.177–0.458) 0.3850	-0.335 (-1.144–0.475) 0.4138
Diabetes mellitus	-0.346 (-1.33–0.638) 0.4873	-0.49 (-1.467–0.487) 0.3219
Hypertension	0.84 (0.119–1.561) 0.0230*	0.86 (0.146–1.575) 0.0188*
Dyslipidemia	0.131 (-0.579–0.842) 0.7146	0.227 (-0.476–0.931) 0.5230
DAS28-ESR (≥ 3.2)	-0.203 (-1.037–0.631) 0.6303	0.263 (-0.546–1.072) 0.5202
ABT treatment	-0.711 (-1.462–0.04) 0.0632	-0.771 (-1.466 – -0.075) 0.0303*

Abbreviations: ABT: abatacept; BMI: body mass index; DAS28: disease activity score in 28 joints; ESR: erythrocyte sedimentation rate

ISSN: 1478-6362